Satraplatin
CAS No. 129580-63-8
Satraplatin ( BMS-182751;BMY-45594;JM-216 )
Catalog No. M11196 CAS No. 129580-63-8
Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 293 | In Stock |
|
10MG | 426 | In Stock |
|
25MG | 699 | In Stock |
|
50MG | 981 | In Stock |
|
100MG | 1314 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSatraplatin
-
NoteResearch use only, not for human use.
-
Brief DescriptionSatraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis.
-
DescriptionSatraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis; shows similar cytotoxicity and pattern of cytotoxicity to cisplatin against human ovarian carcinoma cell lines (IC50=1.7 uM); shows antitumor selectivity far superior to cisplatin, carboplatin, or tetraplatin in vivo; orally active. Chemotherapeutic Agents, Phase 2 Clinical
-
SynonymsBMS-182751;BMY-45594;JM-216
-
PathwayCell Cycle/DNA Damage
-
TargetDNA Alkylator
-
RecptorDNA Alkylator
-
Research AreaCancer
-
IndicationChemotherapeutic
Chemical Information
-
CAS Number129580-63-8
-
Formula Weight500.28
-
Molecular FormulaC10H22Cl2N2O4Pt+2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 33 mg/mL
-
SMILESCC(O[Pt]([NH2]C1CCCCC1)(Cl)(Cl)([NH3])OC(C)=O)=O
-
Chemical NamePlatinum, bis(acetato-κO)amminedichloro(cyclohexanamine)-, (OC-6-43)- (9CI)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kelland LR, et al. Cancer Res. 1993 Jun 1;53(11):2581-6.
2. Mellish KJ, et al. Br J Cancer. 1993 Aug;68(2):240-50.
3. Ricart AD, et al. Clin Cancer Res. 2009 Jun 1;15(11):3866-71.
2. Mellish KJ, et al. Br J Cancer. 1993 Aug;68(2):240-50.
3. Ricart AD, et al. Clin Cancer Res. 2009 Jun 1;15(11):3866-71.
molnova catalog
related products
-
Oxaliplatin
A platinum-based antineoplastic agent that works by blocking the duplication of DNA; forms both inter- and intra-strand cross links in DNA, prevents DNA replication and transcription, causing cell death.
-
Quinacrine dihydroch...
An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.
-
Alchemix
A dual action as an alkylating agent and topoisomerase inhibitor with potent activity against anthracycline- and cisplatin-resistant tumor cancer.